First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., ...More

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.26, no.7, pp.774-780, 2014 (SCI-Expanded) identifier identifier identifier


Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.